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rognostic Indicators
seful for Clinical Care?*
tephen S. Gottlieb, MD, FACC
altimore, Maryland
o we really need another study looking at prognostic
ndicators of mortality of heart failure patients? After all,
nnumerable studies demonstrate the predictive importance
f a slew of natriuretic peptides, inflammatory markers, and
lectrocardiographic parameters, not to mention countless
emographic and readily available blood tests. However,
ave they improved clinical care?
At this point, the answer is probably “no.” Do we (and
hould we) treat a patient differently because the B-type
atriuretic peptide concentration suggests a high mortality
ate? Hopefully, we maximize medications for all pa-
ients. Should blood transfusions be administered because
nemia is a poor prognostic sign? Such a reaction would
ssume that the anemia is the cause of the worse
utcome, a questionable hypothesis. Do we place defi-
rillators because of decreased heart rate variability? At
resent, devices are placed because of the results of
andomized studies and clinical judgment.
See page 334
One could interpret the excellent study by Kalogeropou-
os et al. (1) in this issue of the Journal as providing more
easons to not care about prognostic studies. For reasons we
on’t understand, prognostic factors in virtually all cardio-
ascular disease are different on the basis of race. Despite
ontrolling for multiple factors (including risk factors,
ymptoms, demographic variables, and comorbidities) in
egression models, many studies have shown an unexplained
mpact of ethnicity. For example, in the SWAN (Study of
omen’s Health Across the Nation) study, African Amer-
cans had elevated C-reactive protein concentrations as
ompared with whites, whereas Japanese and Chinese
omen had lower levels (2). Similarly, the likelihood of
ignificant coronary artery disease and in-hospital mortality
n the American College of Cardiology–National Cardio-
ascular Data Registry varied significantly by ethnicity and
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From the Division of Cardiology, University of Maryland, Baltimore, Maryland.ex (3). Intracerebral bleeds were seen more in African
mericans, Hispanics, and Asians with atrial fibrillation
han in whites (4).
The reasons for these differences are not known. Genetic
ariation might be the explanation, and the significance of
olymorphisms is actively being studied (5). However, it is
lso possible that we are just missing knowledge of impor-
ant lifestyle characteristics affecting prognosis or neglecting
o control for an important risk factor. Whatever the reason,
hese studies all point out the limitations of regression
nalyses, which do not (and cannot) control for the multiple
actors that impact prognosis.
A prognostic indicator can also be limited by differences
n the disease process. Perhaps the findings of Kalogero-
oulos et al. (1) reflect that the physiology of acute heart
ailure is qualitatively different from that of chronic heart
ailure. Even the impact of proven (chronic) treatments
ight be altered in the acute state. These considerations
hould alert us to considering as many factors as possible
and realizing the differences among individuals) when
valuating and treating patients.
But the many limitations discussed in the preceding text
nd the common concern that patients all need to be treated
s individuals should not blind us to the utility of the Seattle
eart Failure Model or similar tools. There is one area
here prognosis should be paramount in our thinking and
ur knowledge has not been translated into action: the
iming of transplantation and left ventricular assist device
LVAD) implantation. Most programs still use a peak
xygen consumption (usually with a cutoff of 14 ml/kg/min)
s a major factor to define appropriateness of transplanta-
ion. This derives from a study from 1991 (!) (6) and is used
espite the knowledge that many factors affect oxygen
onsumption (7).
There is increasing realization that data-driven conclu-
ions might be more accurate than clinical judgment in
any medical circumstances. In the emergency room, na-
riuretic peptide concentrations seem better than clinical
udgment (8). In cancer, objective parameters predict
ortality better than physicians (or committees) (9).
ndeed, a meta-analysis of comparisons of clinical and
echanical (defined as formal, statistical) predictions in
arious circumstances showed the superiority of the
echanical (10).
This should not be surprising. Physicians are more likely
o be influenced by a short-term perspective, whereas clearly
long-term perspective is needed when considering trans-
lantation and LVAD use. In many circumstances, such as
n patients after myocardial infarction or with chronic heart
ailure, the use of evidence-based medicine has clearly
mproved outcomes. Yet, the emotion associated with hos-
italized patients with heart failure has prevented us from
ooking critically at data regarding these patients, even
hough there are signs that we might not be transplanting
he correct patients. Shouldn’t we be concerned that status
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ith transplantation (11)?
What message should we take from the study by Kalog-
ropoulos et al. (1) about prognostication? We could focus
n the demonstrated limitations of prognostication. Yes,
here are factors we do not understand. The calculated
rognosis might be influenced by the specific patient pop-
lation evaluated. Race and acuity seem to impact the
rognostic ability and can change the expected mortality.
he use of defibrillators might influence mortality slightly
ifferently than predicted. Undoubtedly, there are modify-
ng factors omitted in all models that attempt to quantify
xpected prognosis of patients with heart failure.
More appropriate, however, would be to look at how
uch information we can derive from well-designed and
ested heart failure scores. In 2008 we can reliably predict
he risk of mortality of heart failure patients. We will never
now with certainty what will happen to an individual
atient, but tested scores are better than clinical judgment in
nowing the chances of death for that patient. Although
uture modifications will continue to improve predictive
odels, present imperfections should not prevent us from
ealizing that we can now identify black and white, acute
nd chronic patients who will have a better outcome with
edical therapy than that expected with transplantation (or
ice versa). It is time for transplantation selection com-
ittees and physicians implanting LVADs to use the
ost objective evidence to determine which patients are
ikely to be helped and which will be harmed by surgical
ntervention. We can reliably compare the expected
edical prognosis with that of transplantation or LVAD
mplantation (12).
Whether the Seattle Heart Failure Model, a modifica-
ion, or a different prognostic indicator is used, transplants
hould not be performed in people with a good predicted
utcome. Left ventricular assist devices should not be
mplanted when the predicted mortality is worse with the
ntervention than without. There are too many patients who
an benefit from transplantation and too much money spent
n counterproductive procedures to continue to use out-
ated criteria. Physicians might all believe that their own
udgment is exceptional, but medical care will improve and Ke more cost effective if advanced heart failure treatment is
ased upon data and logical thinking.
eprint requests and correspondence: Dr. Stephen S. Gottlieb,
ivision of Cardiology, University of Maryland, 22 South Greene
treet, Baltimore, Maryland 21201. E-mail: sgottlie@medicine.
maryland.edu.
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